154 related articles for article (PubMed ID: 7908126)
1. The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy.
Zadow B; Schmidt WJ
Naunyn Schmiedebergs Arch Pharmacol; 1994 Jan; 349(1):61-5. PubMed ID: 7908126
[TBL] [Abstract][Full Text] [Related]
2. The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine.
Hauber W; Andersen R
Naunyn Schmiedebergs Arch Pharmacol; 1993 Nov; 348(5):486-90. PubMed ID: 8114947
[TBL] [Abstract][Full Text] [Related]
3. The AMPA receptor antagonist GYKI 52466 reverses the anti-cataleptic effects of the competitive NMDA receptor antagonist CGP 37849.
Hauber W; Waldenmeier MT
Eur J Pharmacol; 1994 May; 256(3):339-42. PubMed ID: 7913894
[TBL] [Abstract][Full Text] [Related]
4. Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist.
Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
Pol J Pharmacol; 1995; 47(6):501-7. PubMed ID: 8868372
[TBL] [Abstract][Full Text] [Related]
5. Morphine-induced catalepsy is augmented by NMDA receptor antagonists, but is partially attenuated by an AMPA receptor antagonist.
Tzschentke TM; Schmidt WJ
Eur J Pharmacol; 1996 Jan; 295(2-3):137-46. PubMed ID: 8720577
[TBL] [Abstract][Full Text] [Related]
6. Behavioural and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats.
Bubser M; Tzschentke T; Hauber W
J Neural Transm Gen Sect; 1995; 101(1-3):115-26. PubMed ID: 8695042
[TBL] [Abstract][Full Text] [Related]
7. Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: comparison with diazepam and interactions with flumazenil.
Löscher W; Hönack D
Br J Pharmacol; 1994 Dec; 113(4):1349-57. PubMed ID: 7889291
[TBL] [Abstract][Full Text] [Related]
8. The role of NMDA and AMPA/Kainate receptors in the consolidation of catalepsy sensitization.
Riedinger K; Kulak A; Schmidt WJ; von Ameln-Mayerhofer A
Behav Brain Res; 2011 Mar; 218(1):194-9. PubMed ID: 21130808
[TBL] [Abstract][Full Text] [Related]
9. Effects of AMPA receptor antagonists on dopamine-mediated behaviors in mice.
Vanover KE
Psychopharmacology (Berl); 1998 Mar; 136(2):123-31. PubMed ID: 9551768
[TBL] [Abstract][Full Text] [Related]
10. N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4- isoxazoleproprionate (AMPA) glutamate-receptor antagonists have different interactions with the discriminative stimuli of abused drugs.
Jackson A; Brown G; Stephens DN
Psychopharmacology (Berl); 1996 Dec; 128(3):320-7. PubMed ID: 8972552
[TBL] [Abstract][Full Text] [Related]
11. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
Bibbiani F; Oh JD; Kielaite A; Collins MA; Smith C; Chase TN
Exp Neurol; 2005 Dec; 196(2):422-9. PubMed ID: 16203001
[TBL] [Abstract][Full Text] [Related]
12. Blocking the trigeminal EPSP in rat abducens motoneurons in vivo with the AMPA antagonists NBQX and GYKI 53655.
Ruiz A; Durand J
Brain Res Bull; 2000 May; 52(2):99-107. PubMed ID: 10808079
[TBL] [Abstract][Full Text] [Related]
13. Allosteric interactions between cyclothiazide and AMPA/kainate receptor antagonists.
Yamada KA; Turetsky DM
Br J Pharmacol; 1996 Apr; 117(8):1663-72. PubMed ID: 8732274
[TBL] [Abstract][Full Text] [Related]
14. Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists.
Papa SM; Engber TM; Boldry RC; Chase TN
Eur J Pharmacol; 1993 Mar; 232(2-3):247-53. PubMed ID: 8385618
[TBL] [Abstract][Full Text] [Related]
15. A comparison of intravenous NBQX and GYKI 53655 as AMPA antagonists in the rat spinal cord.
Chizh BA; Cumberbatch MJ; Headley PM
Br J Pharmacol; 1994 Jul; 112(3):843-6. PubMed ID: 7522860
[TBL] [Abstract][Full Text] [Related]
16. Disruption of operant oral self-administration of ethanol, sucrose, and saccharin by the AMPA/kainate antagonist, NBQX, but not the AMPA antagonist, GYKI 52466.
Stephens DN; Brown G
Alcohol Clin Exp Res; 1999 Dec; 23(12):1914-20. PubMed ID: 10630610
[TBL] [Abstract][Full Text] [Related]
17. AMPA receptor antagonists, GYKI 52466 and NBQX, do not block the induction of long-term potentiation at therapeutically relevant concentrations.
Kapus G; Székely JI; Durand J; Ruiz A; Tarnawa I
Brain Res Bull; 2000 Aug; 52(6):511-7. PubMed ID: 10974490
[TBL] [Abstract][Full Text] [Related]
18. The effect of the non-NMDA receptor antagonist GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures.
Dürmüller N; Craggs M; Meldrum BS
Epilepsy Res; 1994 Feb; 17(2):167-74. PubMed ID: 8194512
[TBL] [Abstract][Full Text] [Related]
19. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models.
Yamaguchi S; Donevan SD; Rogawski MA
Epilepsy Res; 1993 Jul; 15(3):179-84. PubMed ID: 7693450
[TBL] [Abstract][Full Text] [Related]
20. Some behavioral effects of CNQX AND NBQX, AMPA receptor antagonists.
Maj J; Rogóz Z; Skuza G; Jaros T
Pol J Pharmacol; 1995; 47(4):269-77. PubMed ID: 8616504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
